Table 3.

Response and survival outcomes by response to prior AML treatment(s) for patients with R/R AML who received enasidenib 100, mg/day

Refractory to intensive chemotherapy (n = 40)Refractory to lower-intensity therapy (n = 44)Relapsed following any prior AML therapy (n = 130)
ORR, n (%) [95% CI]* 15 (37.5) [22.7-54.2] 19 (43.2) [28.4-59.0] 49 (37.7) [29.4-46.6] 
CR, n (%) 4 (10.0) 12 (27.3) 26 (20.0) 
CRi/CRp, n (%) 4 (10.0) 2 (4.5) 14 (10.8) 
OS, median (95% CI), mo 12.4 (8.2-22.9) 8.0 (5.6-11.7) 8.1 (7.0-9.3) 
Refractory to intensive chemotherapy (n = 40)Refractory to lower-intensity therapy (n = 44)Relapsed following any prior AML therapy (n = 130)
ORR, n (%) [95% CI]* 15 (37.5) [22.7-54.2] 19 (43.2) [28.4-59.0] 49 (37.7) [29.4-46.6] 
CR, n (%) 4 (10.0) 12 (27.3) 26 (20.0) 
CRi/CRp, n (%) 4 (10.0) 2 (4.5) 14 (10.8) 
OS, median (95% CI), mo 12.4 (8.2-22.9) 8.0 (5.6-11.7) 8.1 (7.0-9.3) 
*

ORR included CR, CRi/CRp, MLFS, and PR.

Hypomethylating agents or low-dose cytarabine.